FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Crane Robert					2. Issuer Name and Ticker or Trading Symbol Axcella Health Inc. [ AXLA ]						(Che	eck all application	Person(s) to Issi 10% Ov	vner		
(Last) (First) (Middle) C/O AXCELLA HEALTH INC. 840 MEMORIAL DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 03/16/2022						2	X Officer (give title Other (specify below)  Chief Financial Officer				
(Street) CAMBR (City)			02139 (Zip)	4.	If Ame	endment, [	Oate o	f Original Fil	ed (Mo	onth/Da	y/Year)	Line	) <mark>K</mark> Form fil	ed by One R	ling (Check App eporting Person han One Repon	1
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transar Date (Month/Di				ransactio	action 2A. Deemed Execution Date,		3. Transaction Code (Instr.		rities Acquired (A) or d Of (D) (Instr. 3, 4 and		5. Amoun Securities Beneficia Owned Fo	Forn (D) c (I) (I)	orm: Direct D) or Indirect ) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)		Date Exercisable		iration e	Title	Amount or Number of Shares		(Instr. 4)	(5)	
Stock Option (Right to Buy)	\$1.63	03/16/2022		A <sup>(1)</sup>		125,000		(2)	02/0	08/2032	Common Stock	125,000	\$0	125,000	D	

## **Explanation of Responses:**

1. On February 8, 2022, the Reporting Person was granted an option to purchase 125,000 shares of AXLA common stock, subject to the satisfaction of certain performance criteria. On March 16, 2022, the Issuer's Compensation Committee confirmed that the performance criteria had been met.

2. 25% of the shares underlying this option shall vest and become exercisable on February 8, 2023, with the remainder vesting in twelve equal quarterly installments thereafter, subject to Subject to Reporting Person's continued service on each such vesting date.

By: /s/ Paul Fehlner, Attorney-

in-Fact

\*\* Signature of Reporting Person Date

03/18/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.